Pricing

AveXis Inc (AVXS)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Sean P. Nolan
Employees:
10200
2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN, IL, 60015
972-725-7797

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

AveXis, Inc. operates as a clinical-stage gene therapy company that engages in the research and development of technology specifically for neurological genetic disease treatment. Its proprietary gene therapy candidate, AVXS-101 has been granted orphan drug designation for the treatment of all types of spinal muscular atrophy and fast track designation for the treatment of spinal muscular atrophy type 1. The company was founded by John D. Harkey, Jr. in 2010 and is headquartered in Chicago, IL.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available